Company intelligence / Profile preview

BNJ Biopharma

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

BNJ Biopharma is a South Korean biotechnology company focused on the discovery and development of first-in-class small molecule therapeutics for oncology, immunology, and metabolic diseases. The company utilizes its proprietary AI-driven BNJ-Targeting Platform to identify novel drug candidates that modulate challenging protein-protein interactions. Its lead programs include BNJ-101 for solid tumors and BNJ-102 for autoimmune disorders. BNJ Biopharma aims to address significant unmet medical needs by streamlining the drug discovery process through advanced computational modeling and structural biology.

Therapeutic areas: OncologyImmunologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on BNJ Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNJ Biopharma.

Explore the full profile